A comprehensive assessment of the prognostic role of cell adhesion molecules in acute myeloid leukemia

Jing Cheng¹#, Juan Han²#, Chunyan Lin¹

¹Department of Blood Transfusion, The First Affiliated Hospital of Soochow University, Suzhou, China; ²Department of Laboratory, 904th Hospital of Joint Logistic Support Force of PLA, Suzhou, China

Contributions: (I) Conception and design: C Lin; (II) Administrative support: C Lin; (III) Provision of study materials or patients: J Cheng; (IV) Collection and assembly of data: J Cheng, J Han; (V) Data analysis and interpretation: J Han; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

# These authors contributed equally to this work and should be considered as co-first authors.

Background: The outcomes for patients with acute myeloid leukemia (AML) have been shown to vastly differ, predominantly due to genetic heterogeneity. Cell adhesion molecules (CAMs) concluding numerous genes play an important role in AML. We aimed to systematically assess the expression characteristics of adhesion molecules and their correlation to the outcomes of AML.

Method: A total of 173 patients with AML were enrolled in this study. The genetic expressional information and clinical data sourced in previous studies were collected from the Cancer Genome Atlas (TCGA) database. The expression profiles of 141 CAMs were assessed, and the AML subgroups with specific patterns of expression were identified. The outcomes and clinical features of each AML subgroup were compared to detect the factors associated with prognosis. The differentially expressed genes (DEGs) between each subgroup were identified and the prognostic roles of those molecules were evaluated.

Results: According to subgroup clustering, both the primary cluster_1 and subcluster_1 showed a favorable prognosis compared to that of the other patients (26.3 vs. 17.0 months of overall survival (OS) and 46.5 vs. 15.8 months of OS, respectively). Both of the two subgroups were characterized by depressed human leukocyte antigen (HLA) genes. Assessment of the expression of prognosis-associated CAMs revealed that the expressions of SELE, NRCAM, ITGA4, and SDC1 were positively correlated with AML prognosis, while the expression of LICAM, PDCD1, CD276, SELPLG, and CLDN14 were negatively correlated with AML. Among the abovementioned genes, we detected that the individual gene expressions of NRCAM and VCAM1 were capable of independently predicting OS, and the OS was correlated with CAMs closely enough to enable the construction of models for prognosis prediction [area under the curve (AUC) =0.78 and AUC=0.77, respectively].

Conclusions: This study showed a landscape of the expression of CAMs in AML and identified a distinct subgroup with a significantly favorable prognosis. We detected that CAMs can assist in distinguishing the cohort with long term survival and constructed two models to predict the prognosis. Those CAMs have the potential to be developed as therapy targets in the treatment of AML.

Keywords: Acute myeloid leukemia (AML); cell adhesion molecules (CAMs); subgroup; prognosis

Submitted Nov 03, 2020. Accepted for publication Dec 15, 2020.
doi: 10.21037/tcr-20-3315

View this article at: http://dx.doi.org/10.21037/tcr-20-3315
Introduction

Acute myeloid leukemia (AML) is the most common malignant type of leukemia in adults, is associated with clonal hematopoietic stem-cell disorders, and has shown a disparate response to therapy (1). Although the majority of patients with newly diagnosed AML experience complete morphologic remission following treatment with intensive induction chemotherapy, the outcome in older patients who are unable to receive intensive chemotherapy without unacceptable side effects remains dismal (1,2). Decisions about the choice of postremission therapy in patients with AML currently depend on the identification of a selected set of genetic markers at diagnosis and the detection of residual disease with multiparameter flow cytometry (3). Quantitative molecular evaluation during complete remission could further improve prognostication of outcomes in patients with AML (4). Emerging immunotherapies such as chimeric antigen receptor T cells have advanced the treatment of acute lymphoblastic leukemia (5); so far, most of the targets have been membrane proteins and members of cell adhesion molecule (CAM) sets (6).

The CAMs are specific proteins, which expressed on the cell surface (7). They have been reported to play a critical role in multiple biologic processes, including hemostasis, the immune response, inflammation, embryogenesis, and development of neuronal tissue. There are four main groups: the integrin family, immunoglobulin superfamily, selectins, and cadherins. Membrane proteins that mediate immune cell–cell interactions fall into different categories, namely those involved in antigen recognition, costimulation, and cellular adhesion. Adhesion plays an important role both in normal hematopoiesis and in AML (8). Blasts of AML express many of the CAMs identified on normal hematopoietic precursors. The differential expression of CAMs between normal hematopoietic cells and leukemic blasts has been documented as differently expressed, likely reflecting the heterogeneity of the disease (9). A variety of processes within the bone marrow (BM) are governed by CAMs, including migration, homing, and quiescence. The AML blasts home to BM, as the CAM-mediated interaction with the niche protects them from chemotherapeutic agents. On the contrary, they then detach from the niches and move from the BM into the peripheral blood to colonize other sites such as the spleen and liver, possibly in a process that is reminiscent of epithelial-to-mesenchymal-transition in metastatic solid cancers (10). The expression of CAMs has a prognostic impact and there are ongoing efforts to therapeutically target adhesion in the fight against leukemia (11).

In this study, we elucidate the transcriptional pattern of CAMs in a cohort of 173 patients with AML. All data collected from a precise published work and complete follow-up information were also available. We focused on the prognostic role of assembled genes and sole CAMs, and further sought the independent prognostic factors, which might play crucial roles in the development of AML and emerge as potential immunotherapy targets. We present the following article in accordance with the MADR reporting checklist (available at http://dx.doi.org/10.21037/tcr-20-3315).

Methods

Patients and RNA-seq

The normalized RNA sequencing data of 200 patients were obtained from a public database (cbioportal.org), and the corresponding clinical records were also collected (12). In the previously published study, patients underwent pathological diagnosis and detailed clinical features were recorded, including age, gender, and grade. All 200 patients were diagnosed with AML according to the histological records. Gene expression values were shown as messenger (m)RNA z-score data and compared between each subject. Collectively, there were 27 cases missing related transcriptional information, and 173 eligible cases were enrolled in the final study. All public omics data sets used were generated by previous studies and ethical approval was granted prior to their use. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

Bioinformatics

Genes relevant to CAMs statistics annotated in the Kyoto Encyclopedia of Genes and Genomes (KEGG) database (kegg.jp/hsa04514) were enrolled in the current study (13). After excluding 8 genes lacking expression information, the profiles of 141 genes involved in cell adhesion were assessed in AMLs. A cluster analysis of the genetic expression of integral gene sets was performed to distinguish samples based on gene expression profiles. Participants with similar gene expression patterns were identified from the entire population. The transcriptional levels were shown as mRNA z-scores and clustered using the hierarchical clustering algorithm via a Stanford...
Results

The expression profile of CAMs was significantly associated with AML survival

To investigate the specific AML subpopulation, patients were divided into different groups according to similar CAMs expressing patterns. Primarily, there were two clusters which showed different expression models (Figure 1A). Compared to the outcomes in cluster_2, cluster_1 showed a better OS with an apparent difference (26.3 vs. 17.0 months, P=0.2522); however, cluster_1 had a significantly prolonged PFS (34.1 vs. 13.8 months, P=0.0379) (Figure 1B). We also detected detailed subgroups according to different expression of CAMs, and identified four subclusters in total (Figure 1A). Comparison of the prognostic roles of the chromatin remodeling related genes were investigated by comparing the survivals of different groups. The overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), and disease-specific survival (DSS) were accessed using a GraphPad Prism program (GraphPad Software, Inc., San Diego, CA, USA; Version 8). Comparisons of survival in different clusters revealed the relevance of gene expression profiles and the prognosis. Additionally, an analysis of the difference in OS between the cohorts with low or high expression levels of individual genes was conducted using GraphPad Prism 8.0.

Expression of CAMs was correlated with AML prognosis

We arranged the AML participants in the order of survival status and assessed the prognosis-associated genes from the CAMs. Finally, 21 genes were detected to be significantly associated with the OS of AML (P<0.15 or P<0.05) (Figure 3A). Among those genes, expressions of 10 genes were positively correlated to OS (e.g., SEL and NRCAM); expressions of 9 genes were negatively correlated to OS (e.g., LICAM and PDCD1) (Tables 2, 3). We performed multi-factor regression analysis in order to identify independently prognostic CAMs. In total, there were 5 genes, LICAM, SDC1, NTNG1, CLDN4 and NRCAM, detected as independently correlated with OS. We compared the OS between the high expression subgroup and low expression subgroup regarding single genes. Among those genes, patients with up-regulated NRCAM showed a significantly prolonged OS comparing to the down-regulated cohort (27.0 vs. 11.8 months, P=0.0133) (Table 4, Figure 3B). Up-regulation of SDC1 also indicated a favorable prognosis.
Figure 1 Analysis of CAMs expression showed two primary clusters and four subclusters in AML. (A) Hierarchical clustering divided the entire participant group into different subgroups; (B) the participants in cluster_1 showed a favorable OS and PFS; (C) the participants in subclusters showed different outcomes (Top) and subcluster_1 showed favorable OS and PFS compared to the others (Bottom). CAMs, cell adhesion molecules; AML, acute myeloid leukemia; OS, overall survival; PFS, progression-free survival.
Figure 2 There were different expressions of CAMs in each subgroup. (A) The DEGs between cluster_1 and cluster_2; (B) the DEGs between subcluster_1 and the remaining participants; (C) the different expression of HLA-DMB and HLA-DPA1 in each cohort. CAMs, cell adhesion molecules; DEGs, differentially expressed genes; HLA, human leukocyte antigen.
Table 1 The OS and PFS of clusters and subclusters

| Groups      | OS (month) | P value | PFS (month) | P value |
|-------------|------------|---------|-------------|---------|
| Primary     |            |         |             |         |
| Cluster_1   | 26.3       | 0.2522  | 34.1        | 0.0379* |
| Cluster_2   | 17.0       |         | 13.8        |         |
| Subordinate |            |         |             |         |
| Cubcluster_1| 46.5       | 0.0421* | Undefined   | 0.0137* |
| Others      | 15.8       |         | 13.9        |         |

*P<0.05. OS, overall survival; PFS, progression free survival.

Figure 3 The expression of CAMs associated with AML OS. (A) The heatmaps of OS correlated genes (left: Pearson correlation, right: P value); (B) the different OS of participants with high and low expressed CAMs. CAMs, cell adhesion molecules; AML, acute myeloid leukemia; OS, overall survival.
Table 2 The differentially expressed genes in subclusters

| Genes      | Expression in subcluster_1 | Expression in subcluster_2 | P value  |
|------------|-----------------------------|-----------------------------|----------|
| HLA-DMB    | −1.09005                    | 0.39482                     | 1.17E-22 |
| HLA-DPA1   | −1.08922                    | 0.394519                    | 1.29E-22 |
| HLA-DPB1   | −1.04369                    | 0.378035                    | 2.24E-20 |
| HLA-DRA    | −1.03715                    | 0.375663                    | 4.52E-20 |
| HLA-DRB1   | −0.98212                    | 0.355725                    | 1.12E-17 |
| HLA-DMA    | −0.95678                    | 0.346553                    | 1.15E-16 |
| HLA-DQA1   | −0.95152                    | 0.344645                    | 1.84E-16 |
| HLA-DQA2   | −0.93551                    | 0.338843                    | 7.45E-16 |
| PECAM1     | −0.92947                    | 0.336655                    | 1.25E-15 |
| ITGAL      | −0.92201                    | 0.33396                     | 2.34E-15 |
| HLA-E      | −0.91268                    | 0.330579                    | 5.06E-15 |
| SIGLEC1    | −0.95428                    | 0.262643                    | 4.97E-13 |
| HLA-DQB1   | −0.89226                    | 0.323181                    | 2.61E-14 |
| HLA-DQA2   | −0.87402                    | 0.276047                    | 5.84E-12 |
| HLA-F      | −0.81068                    | 0.293637                    | 9.86E-12 |
| PDCD1LG2   | −0.84749                    | 0.192393                    | 5.04E-09 |
| HLA-DRB5   | −0.75936                    | 0.275041                    | 2.61E-10 |
| ITGB2      | −0.74179                    | 0.268679                    | 7.45E-10 |
| CD40       | −0.72156                    | 0.261351                    | 2.38E-09 |
| SDC3       | −0.74918                    | 0.228917                    | 1.1E-08  |
| VCAN       | −0.70289                    | 0.254594                    | 6.7E-09  |
| ICAM1      | −0.69379                    | 0.251296                    | 1.09E-08 |
| HLA-DOB    | −0.67501                    | 0.244497                    | 2.93E-08 |
| HLA-B      | −0.66667                    | 0.24147                     | 4.48E-08 |
| ITGB7      | −0.65125                    | 0.235891                    | 9.67E-08 |
| CD274      | −0.68406                    | 0.170463                    | 1.34E-06 |
| CD4        | −0.62595                    | 0.226726                    | 3.25E-07 |
| ITGAM      | −0.62033                    | 0.224687                    | 4.21E-07 |
| CD34       | −0.61984                    | 0.224508                    | 4.31E-07 |
| CTLA4      | −0.6669                     | 0.176313                    | 1.88E-06 |
| CD86       | −0.60025                    | 0.217407                    | 1.05E-06 |
| NCAM1      | −0.58578                    | 0.212173                    | 1.96E-06 |
| MAG        | −1.44184                    | −0.64948                    | 1.92E-05 |
| HLA-C      | −0.58124                    | 0.210528                    | 2.39E-06 |

Table 2 (continued)
Table 2 (continued)

| Genes   | Expression in subcluster_1 | Expression in subcluster_2 | P value   |
|---------|----------------------------|----------------------------|-----------|
| GLG1    | -0.55807                   | 0.202134                   | 6.26E-06  |
| CNTNAP1 | -0.54678                   | 0.198043                   | 9.84E-06  |
| CADM1   | -0.56964                   | 0.142971                   | 4.61E-05  |
| CD22    | -0.518                     | 0.187615                   | 2.98E-05  |
| ICOS    | -0.50532                   | 0.183028                   | 4.74E-05  |
| CLDN4   | -0.92952                   | -0.24651                   | 0.001502  |
| CD28    | -0.49706                   | 0.180042                   | 6.38E-05  |
| ESAM    | -0.46811                   | 0.169554                   | 0.000173  |
| CD226   | -0.45431                   | 0.164556                   | 0.000273  |
| NFASC   | -0.61538                   | 0.000243                   | 0.000962  |
| CD6     | -0.44748                   | 0.162079                   | 0.00034   |
| ICOSLG  | -0.41748                   | 0.151217                   | 0.000855  |
| CD8A    | -0.41444                   | 0.150118                   | 0.000935  |
| VSIR    | -0.41267                   | 0.149471                   | 0.000985  |
| PTPRC   | -0.40635                   | 0.147178                   | 0.001184  |
| CDH1    | -0.43675                   | 0.09549                    | 0.002586  |
| TIGIT   | -0.39899                   | 0.111005                   | 0.004502  |
| CDBB    | -0.38757                   | 0.113751                   | 0.004476  |
| ITGA9   | -0.35419                   | 0.12829                    | 0.004865  |
| SEL    | -0.35404                   | 0.128235                   | 0.004884  |
| ITGAV   | 0.411607                   | -0.14909                   | 0.001016  |
| OCLN    | 0.343257                   | -0.301                     | 0.001635  |
| F11R    | 0.510272                   | -0.18482                   | 3.96E-05  |
| CD99    | 0.51868                    | -0.18787                   | 2.9E-05   |
| MPZL1   | 0.549037                   | -0.19886                   | 9E-06     |
| CLDN10  | 0.067996                   | -0.68835                   | 0.000118  |
| ALCAM   | 0.556498                   | -0.20157                   | 6.67E-06  |
| CD99L2  | 0.561252                   | -0.20329                   | 5.5E-06   |
| PVR     | 0.567341                   | -0.2055                    | 4.28E-06  |
| NRXN3   | 0.32957                    | -0.48189                   | 9.59E-06  |
| CNTN1   | 0.14362                    | -0.69853                   | 5.62E-07  |
| SPN     | 0.681146                   | -0.24672                   | 2.13E-08  |
| NTNG2   | 0.722824                   | -0.2618                    | 2.22E-09  |
Table 3 The differentially expressed genes in clusters

| Genes     | Expression in cluster_1 | Expression in cluster_2 | P value   |
|-----------|--------------------------|--------------------------|-----------|
| HLA-DMB   | -0.81386                 | 0.594116                 | 2.54E-26  |
| HLA-DPA1  | -0.79287                 | 0.578797                 | 1.4E-24   |
| HLA-DRA   | -0.78532                 | 0.573288                 | 5.52E-24  |
| HLA-DPB1  | -0.77898                 | 0.568658                 | 1.7E-23   |
| HLA-DRB1  | -0.77563                 | 0.566208                 | 3.06E-23  |
| HLA-DMA   | -0.74841                 | 0.546344                 | 2.84E-21  |
| HLA-DQA1  | -0.73524                 | 0.536722                 | 2.22E-20  |
| HLA-DQA2  | -0.66189                 | 0.483176                 | 5.21E-16  |
| PECAM1    | -0.59994                 | 0.43795                  | 5.62E-13  |
| ITGAL     | -0.56436                 | 0.411991                 | 1.85E-11  |
| ITGB2     | -0.50369                 | 0.367694                 | 3.43E-09  |
| ITGB7     | -0.49756                 | 0.363226                 | 5.54E-09  |
| VCAN      | -0.48534                 | 0.354304                 | 1.41E-08  |
| CD86      | -0.47118                 | 0.343958                 | 4E-08     |
| CD4       | -0.46371                 | 0.338512                 | 6.82E-08  |
| HLA-E     | -0.44415                 | 0.324236                 | 2.62E-07  |
| SIGLEC1   | -0.49211                 | 0.253827                 | 2.05E-06  |
| ITGAM     | -0.41181                 | 0.300617                 | 2.07E-06  |
| HLA-B     | -0.41113                 | 0.300124                 | 2.15E-06  |
| VSIR      | -0.3992                  | 0.291412                 | 4.39E-06  |
| ICAM1     | -0.3861                  | 0.281859                 | 9.32E-06  |
| PDCD1LG2  | -0.45346                 | 0.18552                  | 9.3E-05   |
| HLA-C     | -0.34751                 | 0.253686                 | 7.28E-05  |
| HLA-F     | -0.31787                 | 0.23205                  | 0.000301  |
| MAG       | -1.14477                 | -0.6524                  | 0.003414  |
| CLDN23    | -0.40655                 | 0.076474                 | 0.004711  |
| PTPRC     | -0.27473                 | 0.200549                 | 0.00182   |
| GLG1      | -0.2595                  | 0.189431                 | 0.003372  |
| CNTNAP1   | -0.25628                 | 0.18708                  | 0.0038    |
| SDC2      | -0.51325                 | -0.07472                 | 0.008187  |
| CD34      | -0.24505                 | 0.17889                  | 0.005699  |
| SELL      | -0.2397                  | 0.174983                 | 0.006873  |
| CD40      | -0.23042                 | 0.168201                 | 0.00943   |
| HLA-DOB   | -0.22227                 | 0.162263                 | 0.012329  |
| CADM1     | -0.25654                 | 0.106812                 | 0.022345  |

Table 3 (continued)
Table 3 (continued)

| Genes   | Expression in cluster_1 | Expression in cluster_2 | P value     |
|---------|--------------------------|--------------------------|-------------|
| SDC3    | -0.2138                  | 0.102174                 | 0.047718    |
| HLA-G   | -0.18217                 | 0.132977                 | 0.040877    |
| CLDN22  | -1.04872                 | -0.89151                 | 0.04586     |
| CD40LG  | 0.178337                 | -0.13019                 | 0.045359    |
| CDH1    | 0.13824                  | -0.18055                 | 0.04523     |
| SELP    | 0.171721                 | -0.15857                 | 0.037128    |
| CD99L2  | 0.194518                 | -0.142                   | 0.028863    |
| ITGB8   | 0.179977                 | -0.17933                 | 0.022967    |
| IGSF11  | -0.25645                 | -0.62121                 | 0.018708    |
| VCAM1   | 0.043248                 | -0.32297                 | 0.030792    |
| NLGN2   | 0.211922                 | -0.15471                 | 0.017124    |
| SDC1    | 0.203079                 | -0.17684                 | 0.015446    |
| LRRC4   | 0.235182                 | -0.17168                 | 0.008029    |
| NECTIN3 | -0.05646                 | -0.5135                  | 0.010228    |
| NRXN1   | -0.54641                 | -1.01344                 | 0.00734     |
| LRRC4C  | -0.64619                 | -1.11556                 | 0.004531    |
| NLGN4X  | -0.22064                 | -0.69718                 | 0.009706    |
| NEO1    | 0.288804                 | -0.21083                 | 0.001065    |
| CDH15   | -0.54425                 | -1.05122                 | 0.004088    |
| ALCAM   | 0.293719                 | -0.21442                 | 0.000867    |
| PTPRF   | 0.294229                 | -0.21479                 | 0.000849    |
| CDH2    | -0.11512                 | -0.66352                 | 0.000543    |
| MPZL1   | 0.327971                 | -0.23942                 | 0.000188    |
| CLDN5   | 0.28767                  | -0.28726                 | 0.000306    |
| F11R    | 0.3331                   | -0.24316                 | 0.000148    |
| CADM3   | -0.34015                 | -0.94207                 | 4.44E-05    |
| CD80    | 0.380555                 | -0.27781                 | 1.27E-05    |
| ITGAV   | 0.400541                 | -0.2924                  | 4.06E-06    |
| NECTIN1 | 0.40057                  | -0.29241                 | 4.05E-06    |
| JAM3    | 0.407682                 | -0.29761                 | 2.65E-06    |
| OCLN    | 0.278019                 | -0.42733                 | 0.000103    |
| SPN     | 0.432433                 | -0.31568                 | 5.66E-07    |
| NLGN1   | -0.12153                 | -0.88699                 | 1.08E-07    |
| CNTN1   | -0.02019                 | -0.80632                 | 1.61E-07    |
| PVR     | 0.498486                 | -0.3639                  | 5.16E-09    |
| NTNG2   | 0.507862                 | -0.37073                 | 2.46E-09    |
| NRXN3   | 0.24736                  | -0.64097                 | 3.8E-08     |
| CLDN10  | 0.10139                  | -0.91694                 | 2.37E-09    |
in AML, but only with a slight significance (P=0.0531) (Table 4, Figure 3B). Moreover, we divided the entire participant cohort into two groups, a good prognosis group and poor prognosis group, according to their relevant OSs. There were 3 genes, **CLDN14**, **ITGA4**, and **VCAM1**, that were significantly correlated to the assignment to these groups (Table 4, Figure 3B). Among them, up-regulation of **VCAM1** was notably correlated with favorable prognosis in AML (22.3 vs. 11.8 months, P=0.0449).

**The CAMs was capable of predicting OS**

According to the regression analysis, we identified genes that were independently correlated with OS and independently capable of distinguishing the participants into groups with good prognosis or poor prognosis (Table 5). To predict the AML OS, we determined the independent prognostic factors (CAMs) and constructed two OS prediction models. Both of the models had acceptable efficiency to predict the OS (AUC =0.78 and 0.77, respectively) (Figure 4). Statistic evaluation showed that the two models were significant in projecting OS of patients with AML (Table 6).

**Discussion**

In this study, we described the landscape of CAMs that are expressed in AML. Cell adhesion is a process through which cells interact with and attach to neighboring cells or matrix using specialized surface CAMs. Adhesion plays an important role in both normal hematopoiesis and AML. Many of the AMs identified on normal hematopoietic precursors are also expressed by AML blasts. Differential expression of AMs between normal hematopoietic cells and leukemic blasts has been documented as variable, likely reflecting the heterogeneity of the disease. Prognosis is affected by the expression of AMs and efforts continue to be made to therapeutically target adhesion in the fight against leukemia.

---

**Table 4 The OS-correlated CAMs**

| Genes    | Pearson correlation | P value |
|----------|---------------------|---------|
| **SELE** | 0.235               | 0.006   |
| **NRCAM**| 0.233               | 0.006   |
| **ITGA4**| 0.214               | 0.011   |
| **SDC1** | 0.208               | 0.014   |
| **ITGA8**| 0.195               | 0.019   |
| **VCAM1**| 0.194               | 0.020   |
| **NECTIN1**| 0.168             | 0.037   |
| **NLGN4X**| 0.164             | 0.041   |
| **CLDN5**| 0.161               | 0.044   |
| **NTNG2**| 0.160               | 0.045   |
| **JAM3** | −0.157              | 0.048   |
| **ICAM2**| −0.161              | 0.044   |
| **PVR**  | −0.180              | 0.028   |
| **CD80** | −0.199              | 0.017   |
| **CLDN14**| −0.202             | 0.016   |
| **SELPLG**| −0.204            | 0.015   |
| **CD276**| −0.207              | 0.014   |
| **PDCD1**| −0.230              | 0.007   |
| **L1CAM**| −0.244              | 0.005   |

OS, overall survival; CAMs, cell adhesion molecules.
Different expression profiles revealed discrepant outcomes of AML. Both the primary cluster_1 (participants, n=73) and subcluster_1 (n=46) showed significantly prolonged OS and PFS compared to the other groups. All the differences showed statistical significance (P<0.05) except the discrepancy in OS between cluster_1 and cluster_2 (26.3 vs. 17.0 months), which could be attributed to the limited subject size. Evaluation of the differently expressed CAMs indicated that the down-regulation of HLA-relevant genes was associated with a favorable prognosis in AML. Most of the prognosis-related HLAs belonged to major histocompatibility complex (MHC) class II antigen. Among those HLAs, HLA-DMB was shown as a representative molecule and reported to play a critical role in the releasing of class II-associated invariant chain peptide (CLIP) from newly synthesized MHC class II molecules (16). A previous study showed that HLA-DM expression on myeloid leukemic blasts correlated with a poor outcome, which is concordant with our finding (17). Another expression differential of MHC class II genes, HLA-DPA1, was also significantly down-regulated in the favorable prognosis groups (Figure 2C). However, this result contrasts with a previous study, which showed that the HLA-DPA1 expression was specifically depressed in patients with relapse after transplantation or chemotherapy (18). We speculated that this discordance was caused by dynamic changes in the expression of HLAs in AML.

In the regression analysis for the detection of OS-correlated CAMs, neuronal cell adhesion molecule (NRCAM) was uncovered as an independent predictor and the expression was positively correlated with prolonged OS in AML. There is an involvement of NRCAM in the protein binding of heterotypic cell-cell adhesion, and NRCAM was reported to be inhibited by miR-29a and transcriptionally coactivated by Ski protein in AML (19). Previous studies have also shown that NRCAM is a potentially prognostic biomarker in solid tumors, such as glioma (20) and gastric cancer (21). The vascular cell adhesion molecule-1 (VCAM1) is involved in leukocyte-endothelial cell adhesion and interacts with integrin alpha-4/beta-1 (ITGA4/ITGB1) on leukocytes (22). In the current study, VCAM1 was notably and positively correlated with OS; moreover, up-regulation of VCAM1 was seen to independently predict a favorable prognosis in AML. Consistently, previous articles have reported that VCAM1

| Table 5 | The prognostic roles of independent prediction genes |
| Genes | Low expression | High expression | P value | HR | 95% CI of ratio |
|-------|----------------|----------------|---------|----|---------------|
| L1CAM | 18.1           | 18.5           | 0.4139  |    |               |
| SDC1  | 15.8           | 25.8           | 0.0531  |    |               |
| NTING1| 24.1           | 16.4           | 0.6139  |    |               |
| CLDN14| 21.5           | 17.4           | 0.8518  |    |               |
| NRCAM | 11.8           | 27.0           | 0.0133  | 1.599 | 1.103–2.318   |
| VCAM1 | 11.8           | 22.3           | 0.0449  | 1.378 | 0.9464–2.005  |
| ITGA4 | 13.6           | 24.6           | 0.2778  |    |               |

CI, confidence interval; HR, hazard ratio.

Figure 4 The ROC curves of two OS prediction models. ROC, receiver operating characteristic; OS, overall survival.

© Translational Cancer Research. All rights reserved.  Transl Cancer Res 2020;9(12):7605-7618 | http://dx.doi.org/10.21037/tcr-20-3315
was more highly expressed on normal cells compared with leukemic bone marrow stromal cells. These findings suggest that the expression of NRCAM and VCAM1 are efficient predictive markers in AML.

Finally, based on the regression analysis, we constructed two prediction models for indicating the prognosis of AML. Both of the models showed a good efficiency and had AUCs of 0.78 and 0.77, respectively. The results suggested that the RNA-seq data of CAMs have the potential to predict OS. However, since the study is limited to a retrospective data set and has not been verified in the prospective subjects, determining its prognostic roles of CAMs requires further exploration. The specific mechanisms of CAMs to promote or suppress the AML also need to be deeply investigated.

**Conclusions**

In conclusion, we used data obtained from a public database to retrospectively analyze the expression profiles of CAMs and the prognostic roles of sole genes of CAMs in 173 patients with AML. According to gene expression values, specific subgroups with favorable prognoses and independent OS prediction genes were identified. Prospective clinical studies are required for further validation of these results.

**Acknowledgments**

None.

**Footnote**

Reporting Checklist: The authors have completed the MADR reporting checklist. Available at http://dx.doi.org/10.21037/tcr-20-3315

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr-20-3315). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All public omics data sets used were generated by previous studies and ethical approval was granted prior to their use. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
References

1. Döhner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med 2015;373:1136-52.

2. Short NJ, Zhou S, Fu C, et al. Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis. JAMA Oncol 2020;6:1890-9.

3. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med 2016;374:2209-21.

4. Xu M, Zhao XL, Zhu Y, et al. ND4 mutations are more prevalent in patients with acute myeloid leukemia of M2 morphology. Transl Cancer Res 2018;7:1064-71.

5. Willier S, Rothämel P, Hastreiter M, et al. CLEC12A and CD33 co-expression as preferential target on pediatric AML for combinatorial immunotherapy. Blood 2020. [Epub ahead of print].

6. Kupsa T, Horacek JM, Jebavy L. The role of adhesion molecules in acute myeloid leukemia and (hemato)oncology: a systematic review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2015;159:1-11.

7. Gruszka AM, Valli D, Restelli C, et al. Adhesion Deregulation in Acute Myeloid Leukaemia. Cells 2019;8:66.

8. Zhang H, Nakauchi Y, Köhnke T, et al. Potential Role of Adhesion Molecules on Lung Metastasis Enhanced by Local Inflammation. Anticancer Res 2020;40:6171-8.

9. Horiguchi H, Tsuchimoto H, Shinomiya N, et al. A Potential Role of Adhesion Molecules in Acute Myeloid Leukemia. Nat Cancer 2020;1:826-39.

10. Horiguchi H, Tsujimoto H, Shinomiya N, et al. A Potential Role of Adhesion Molecules on Lung Metastasis Enhanced by Local Inflammation. Anticancer Res 2020;40:6171-8.

11. Bae MH, Oh SH, Park CJ, et al. VLA-4 and CXCR4 expression levels show contrasting prognostic impact (favorable and unfavorable, respectively) in acute myeloid leukemia. Ann Hematol 2015;94:1631-8.

12. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013;6:pl1.

13. Zhang Z, Yu H, Jiang S, et al. Evidence for Association of Cell Adhesion Molecules Pathway and NLGN1 Polymorphisms with Schizophrenia in Chinese Han Population. PLoS One 2015;10:e0144719.

14. de Hoon MJ, Imoto S, Nolan J, et al. Open source clustering software. Bioinformatics 2004;20:1453-4.

15. Saldanha AJ. Java Treeview—extensible visualization of microarray data. Bioinformatics 2004;20:3246-8.

16. Webers DA, Evavold BD, Jensen PE. Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM. Science 1996;274:618-20.

17. Chamuleau ME, Souwer Y, Van Ham SM, et al. Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome. Cancer Res 2004;64:5546-50.

18. Christopher MJ, Petti AA, Rettig MP, et al. Immune Escape of Relapsed AML Cells after Allogeneic Transplantation. N Engl J Med 2018;379:2330-41.

19. Teichler S, Illmer T, Roemhild J, et al. MicroRNA29a regulates the expression of the nuclear oncogene Ski. Blood 2011;118:1899-902.

20. Hu G, Wang R, Wei B, et al. Prognostic Markers Identification in Glioma by Gene Expression Profile Analysis. J Comput Biol 2020;27:81-90.

21. Liu JB, Jian T, Yue C, et al. Chemo-resistant Gastric Cancer Associated Gene Expression Signature: Bioinformatics Analysis Based on Gene Expression Omnibus. Anticancer Res 2019;39:1689-98.

22. Becker PS, Kopecky KJ, Wilks AN, et al. Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia. Blood 2009;113:866-74.

© Translational Cancer Research. All rights reserved.